Vericel shares tumble 7% as revenue misses estimates in Q2

Published 31/07/2025, 15:32
Vericel shares tumble 7% as revenue misses estimates in Q2

Investing.com -- Vericel Corporation (NASDAQ:VCEL) shares fell 7.4% after the advanced therapies company reported second-quarter revenue that fell short of analyst expectations, despite posting better-than-expected earnings.

The sports medicine and burn care specialist reported Q2 revenue of $63.2 million, missing the consensus estimate of $64.61 million. However, the company’s loss per share came in at -$0.01, beating analyst expectations of -$0.03. The revenue shortfall overshadowed the earnings beat, driving the significant stock decline.

Total (EPA:TTEF) revenue increased 20% compared to $52.7 million in the same quarter last year, driven by MACI net revenue growth of 21% to $53.5 million. Burn Care revenue reached $9.8 million, consisting of $8.6 million from Epicel and $1.2 million from NexoBrid, with NexoBrid revenue increasing 52% YoY.

"The Company delivered another quarter of solid financial and business results in the second quarter, with significant revenue growth and even higher profitability growth and margin expansion as well as continued strength in the key performance indicators for the MACI Arthro launch," said Nick Colangelo, President and CEO of Vericel.

Gross margin improved to 74%, an increase of more than 400 basis points compared to the prior year. Non-GAAP adjusted EBITDA increased 112% to $13.4 million, with adjusted EBITDA margin expanding by over 900 basis points to 21%.

The company reaffirmed its guidance for MACI full-year revenue growth in the low 20% range and updated its Burn Care revenue guidance for the second half of 2025 to approximately $10 million per quarter, in line with recent performance. Vericel also maintained its full-year profitability guidance of 74% gross margin and 26% adjusted EBITDA margin.

As of June 30, 2025, Vericel had approximately $164 million in cash and investments with no debt.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.